Doug Kelly received a BA in Biochemistry and Molecular Biology from the University of California at San Diego, an M.D. from the Albert Einstein College of Medicine, and an MBA from Stanford. Prior to joining Alloy Ventures, he worked for two European venture capital firms, as well as Ligand Pharmaceuticals, and as an independent consultant. He was a seed- or early-stage investor in Favrille (NASDAQ: FVRL), Macusight and Novasys, and is also a director of Adiana, Arbor Surgical, BARRx, Crux Biomedical, KaloBios, Pharsight (NASDAQ:PHST.OB) and Restoration Robotics. Additionally, Doug teaches Stanford University’s, Business 16; "Financing The Start-up."